Letters to the Editor

Complement C1s inhibition with sutimlimab results in durable response in cold agglutinin disease: CARDINAL study 1-year interim follow-up results

Department of Hematology and Stem Cell Transplantation, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen
Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan
UCLH Centre for Waldenstrom’s Macroglobulinemia and Related Conditions, University College London Hospitals NHS Foundation Trust, London
Thrombosis and Hemostasis Center, Saitama Medical University Hospital, Saitama
Division of Hematology, MedStar Georgetown University Hospital, Washington
Henri-Mondor University Hospital, Assistance Publique-Hopitaux de Paris, UPEC, Creteil
Division of Hematology, Massachusetts General Hospital, Harvard Medical School, Boston
Department of Clinical Pharmacology, Medical University of Vienna, Vienna
Section for Hematology, Department of Medicine, Haukeland University Hospital, Bergen
Keck School of Medicine of USC, Los Angeles, CA
Sanofi, Cambridge
Sanofi, Cambridge
Sanofi, Cambridge
Sanofi, Cambridge
Sanofi, Cambridge
Sanofi, Cambridge
Department of Research and Innovation, Haugesund Hospital, Haugesund
Vol. 107 No. 7 (2022): July, 2022 https://doi.org/10.3324/haematol.2021.279812